FindTrial
Sign In

Comparison of Remifentanil and Dexmedetomidine in Controlling Blood Pressure and Heart Rate During Laparoscopic Gallbladder Surgery: A Double-Blind Randomized Study

Effects of Remifentanil Versus Dexmedetomidine on Hemodynamic Response to Pneumoperitoneum During Laparoscopic Cholecystectomy A Double-Blind Randomized Controlled Study - Nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105677
Enrollment
54
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Receiving Dexmedetomidine Preparation for 4 mcg/mL in 50 mL Syringe Dexmedetomidine is supplied as a 200 mcg/2 mL vial (100 mcg/mL concentration). Withdraw 2 mL (200 mcg) of Dexmedetomi

Sponsors

D Y Patil University School of Medicine and Hospital Nerul Navi Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA Grade I and II Patients undergoing elective Laparoscopic Cholecystectomy under general anaesthesia. Patients giving consent for the study

Exclusion criteria

Exclusion criteria: Patients with morbid obesity severe hepatic or renal disease Cardiac dysfunction and pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
To compare the Haemodynamic effects of Remifentanil and Dexmedetomidine during CO2 Inflation (Pneumoperitoneum) during Laparoscopic Cholecystectomy.Timepoint: 1 to 2 hr—

Secondary

MeasureTime frame
To assess postoperative recovery profile including sedation & pain scores. To assess the incidence of adverse effects (Bradycardia Hypotension Chest wall rigidity Nausea Vomiting respiratory depression) related to each drugTimepoint: 1 to 2 hr—

Countries

India

Contacts

Public ContactDr Shraddha sunil sirigeri

padmashree d y patil school of medicine navi mumbai

gbalasaheb690@gmail.com9819631719

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026